22nd Century Group (Nasdaq: XXII) to Participate in LD Micro, Roth Capital Investor Meetings

Rhea-AI Summary

On May 27, 2022, 22nd Century Group, a leading agricultural biotechnology company focused on reducing nicotine tobacco and advanced plant technologies, announced investor meetings at two upcoming conferences in June 2022. The first event is the LD Micro Invitational XII on June 7, 2022, with a presentation scheduled for 8:00 a.m. PT at the Four Seasons Hotel in California. The second event is the 8th Annual Roth London Conference on June 22, 2022, held in London. Investors can schedule meetings through institutional representatives or by contacting the company's investor relations.

BUFFALO, N.Y., May 27, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced that James A. Mish, Chief Executive Officer, and Richard Fitzgerald, Chief Financial Officer, will host meetings with investors at two upcoming investor conference events in June 2022.

Event:	LD Micro Invitational XII (in person)
Date:	Tuesday, June 7, 2022
Format:	Group presentation and individual meetings
Presentation:	8:00 a.m. Pacific Time
Live stream:	https://ldinv12.mysequire.com/
Location:	Four Seasons Hotel, Westlake Village, CA
Event:	8th Annual Roth London Conference (in person)
Date:	Wednesday, June 22, 2022
Format:	Individual meetings
Location:	InterContinental London Park Lane, London, U.K.

Institutional investors participating in the conference can request a meeting with management through their institutional representative, or by contacting 22nd Century Group’s investor relations team via investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, The Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021, now in a pilot marketing program in the United States. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube. Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 1, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact:
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
T: 716-300-1221
mkuo@xxiicentury.com

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
mkreps@darrowir.com

FAQ

What is 22nd Century Group's focus regarding plant technology?

22nd Century Group specializes in agricultural biotechnology aimed at reducing nicotine in tobacco and advancing hemp/cannabis and hops plant technology.

When is the LD Micro Invitational XII where 22nd Century Group will present?

The LD Micro Invitational XII is scheduled for June 7, 2022, with a presentation at 8:00 a.m. Pacific Time.

Where will the 8th Annual Roth London Conference take place?

The 8th Annual Roth London Conference will be held at the InterContinental London Park Lane on June 22, 2022.

How can institutional investors meet with 22nd Century Group during the conferences?

Institutional investors can request a meeting with management through their representatives or by contacting 22nd Century Group's investor relations team.

What significant FDA approval did 22nd Century Group receive?

22nd Century Group received the first and only FDA MRTP authorization for a combustible cigarette in December 2021, which is part of its pilot marketing program.